[ad_1]
A handful of candidate vaccines towards Covid-19 have reported efficacy ranges of larger than 90 per cent in medical trials, and Aylward famous that a number of vaccine platforms have proven sturdy outcomes.
“If you look week by week at the number of companies that are announcing positive results in terms of the efficacy of vaccines, that number is increasing and what’s important is it’s increasing not just in terms of the number of products, but also the different technology platforms that they are being built on. As we’ve seen now, there are three different sorts of technology platforms, as we call them, that have reported very positive efficacy and safety data,” the WHO senior adviser informed a media briefing.
Over the previous week, US media retailers reported that Pfizer is unlikely to fulfill its authentic provide targets for its vaccine towards Covid-19, which is produced along side German agency BioNTech, as a consequence of provide chain points.
GlaxoSmithKline and Sanofi additionally introduced earlier on Friday that their candidate vaccine will seemingly not be accessible till the tip of 2021 as a consequence of disappointing trial outcomes, and Aylward famous the WHO’s concern over the precise quantity of accessible vaccine doses.
“But at the same time … there are real challenges with volumes. These are still very, very scarce products. And just as some companies are announcing successes, there are others – and we’ve had two over the last few days – that have said they have had challenges with their products either in terms of the volumes they can produce or in terms of some of the trial results,” the WHO senior adviser stated.
At the identical media briefing, WHO Director-General Tedros Adhanom Ghebreyesus expressed his perception that extra nations will start their mass coronavirus illness vaccination applications within the close to future.
(This story has not been edited by Newslivenation employees and is auto-generated from a syndicated feed.)